Felix Pharmaceuticals
- Company typePrivate
- Founded2015
- HeadquartersDublin, Ireland
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Felix Pharmaceuticals does
Felix Pharmaceuticals is a Dublin-headquartered veterinary pharmaceutical company that develops, manufactures, and markets bio-equivalent generic medicines exclusively for the companion animal segment, including dogs, cats, and horses. The company's product portfolio spans more than 24 commercially marketed products across NSAIDs, antibacterials, antiparasitics, antiemetics, antithyroid, behavioral, and sedative therapeutic categories, offered in multiple formats including flavored tablets, chewables, soft chewables, caplets, oral suspensions, and injectables. Manufacturing is concentrated at 20 plants in India (notably in Pithampur and Greater Noida), supported by an R&D center in Greater Noida and a 16,000 square meter cGMP-compliant facility producing conventional, value-added, and complex generics.
The company reports 250+ FDA approvals and a development pipeline of 65+ products at various stages of US FDA approval, with 10 products currently commercially sold in the US market through its Kansas City-based subsidiary, Felixvet Inc. Felix monetizes through a combination of direct sales to veterinarians and pet owners, licensing arrangements with distribution partners, and contract manufacturing services offered to other animal health companies. The company is privately held following a $175 million minority investment from Advent International in June 2025, intended to support global growth, and is governed by a board that includes senior pharma executives such as Sir Jonathan Symonds (Chair of GSK) and Ian Jacobson (former CEO of Cobalt Pharmaceuticals).
Felix Pharmaceuticals firmographics
Firmographics- Name
- Felix Pharmaceuticals
- Legal name
- Felix Generics Private Limited
- Website
- https://felixvet.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Felix Pharmaceuticals industry classification
Industry- Product category
- Veterinary Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro industry
- Generic & Private-Label Veterinary PharmaceuticalsCompanion Animal Therapeutics (Rx)
Keywords
Where Felix Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Dublin
- HQ country
- Ireland
- HQ region
- Europe
Offices6 records
Markets served
Felix Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Product Sales: Direct sales of generic veterinary pharmaceutical products to veterinarians and pet owners. Revenue generated through 10 commercially sold products in the US market.
- Licensing and Direct Sales: Generates revenue via licensing arrangements and direct sales to end customers
Go-to-market motion2 records
Distribution channels2 records
Marketing channels2 records
Felix Pharmaceuticals product offering
Product offeringCore offering
Felix Pharmaceuticals develops, manufactures, and markets high-quality bio-equivalent generic pharmaceutical products exclusively for the companion animal segment (dogs, cats, and horses). Its portfolio covers conventional, value-added, and complex generics across multiple therapeutic categories including NSAIDs, antibacterials, antiparasitics, antiemetics, antithyroid drugs, sedatives, and behavioral medications, delivered in diverse dosage forms. The company sells 10 products commercially in the US, operates 20 manufacturing plants, and holds 250+ FDA approvals with 65+ products in development.
Product overview
Felix Pharmaceuticals is a Dublin-based veterinary pharmaceutical company that develops, manufactures, and markets high-quality generic pharmaceutical products exclusively for the companion animal segment. The company's product portfolio includes over 24 distinct products spanning multiple therapeutic categories: NSAIDs (Carprofen, Firocoxib, Deracoxib, Meloxicam), antibiotics (Enrofloxacin, Marbofloxacin, Cefpodoxime, Clindamycin), antiparasitics (Praziquantel), and specialty medications (Maropitant Citrate for vomiting, Clomipramine for anxiety, Methimazole for hyperthyroidism, Dexmedetomidine/Atipamezole for sedation). Products are offered in multiple delivery formats including flavored tablets, chewable tablets, soft chewables, caplets, oral suspensions, and injectable solutions. The company operates cGMP-compliant manufacturing facilities in India and serves regulated markets including the USA, Europe, and Japan, with 10 products currently commercially sold in the US and a development portfolio of over 65 products at various stages of US FDA approval.
Differentiator
Problem solved
Functional benefit
Brands
- Felix Manufacturing: Modern manufacturing facility spanning 16,000 square meters with three production lines, specializing in plain tablets, chewables, soft chewables, oral liquids, and oral pastes for animal health pharmaceuticals
- Felix Generics
Companies that use Felix Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles2 records
Felix Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Felix Pharmaceuticals partnerships and signals
Strategic signalScale indicators6 records
Recent moves5 records
Expansion highlights5 records
Felix Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Dechra Pharmaceuticals: Dechra is a UK-based specialty veterinary pharmaceuticals company focused on companion animal therapeutics, with a strong portfolio in endocrinology, dermatology, and pain management. It is a direct competitor to Felix in regulated-market companion animal generics and specialty pharma.
- Vetoquinol: Vetoquinol is a French global animal health company with significant companion animal pharmaceutical and generic offerings. Comparable to Felix in product categories (NSAIDs, anti-infectives) and target customer base (veterinarians and pet owners).
- Virbac: Virbac is a France-based global animal health company with a broad portfolio in companion animal pharmaceuticals, vaccines, and parasiticides. Comparable to Felix across multiple therapeutic segments and distribution through veterinary channels.
- Norbrook Laboratories: Norbrook is a UK-based veterinary pharmaceutical manufacturer specializing in generics and anti-infectives for companion and production animals. Comparable to Felix in its FDA-approved manufacturing footprint and focus on affordable generic veterinary drugs.
- Chanelle Pharma: Chanelle is an Ireland-based veterinary pharmaceutical manufacturer producing generic and branded medicines for companion and farm animals. It is a direct peer to Felix, with similar business model and product focus, and serves as an indication of the Irish vet pharma manufacturing ecosystem.
Broad incumbents
- Zoetis: Zoetis is the largest global animal health company with a comprehensive portfolio spanning companion animals, livestock, diagnostics, and devices. It is the originator of many pioneer drugs that Felix seeks to genericize and competes broadly across Felix's product categories.
- Elanco Animal Health: Elanco is a major global animal health company with deep companion animal and livestock offerings. It competes with Felix in NSAIDs, parasiticides, and anti-infectives and is a frequent originator of pioneer drugs now being genericized.
- Phibro Animal Health: Phibro is a diversified animal health and nutrition company with companion animal and livestock pharma offerings. It is comparable to Felix in its focus on cost-effective generics and contract manufacturing.
- Ceva Santé Animale: Ceva is a global animal health company with strong positions in companion animal pharmaceuticals, vaccines, and behavior products. It overlaps with Felix in several therapeutic categories and has similar international distribution.
- Boehringer Ingelheim Animal Health: Boehringer Ingelheim Animal Health is one of the largest global players in companion animal and livestock pharmaceuticals. It is the originator of several pioneer drugs Felix is genericizing and competes across Felix's therapeutic areas.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks1 record
Key highlights7 records
Customer concentration
Felix Pharmaceuticals social profiles
Digital presenceFelix Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Felix Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles7 records
Felix Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries2 records
Felix Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Felix Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Felix Pharmaceuticals
What does Felix Pharmaceuticals do?
Felix Pharmaceuticals develops, manufactures, and markets high-quality bio-equivalent generic pharmaceutical products exclusively for the companion animal segment (dogs, cats, and horses). Its portfolio covers conventional, value-added, and complex generics across multiple therapeutic categories including NSAIDs, antibacterials, antiparasitics, antiemetics, antithyroid drugs, sedatives, and behavioral medications, delivered in diverse dosage forms. The company sells 10 products commercially in the US, operates 20 manufacturing plants, and holds 250+ FDA approvals with 65+ products in development.
Is Felix Pharmaceuticals a public or private company?
Felix Pharmaceuticals is a private company. It is classified as private equity controlled and is currently operating.
When was Felix Pharmaceuticals founded?
Felix Pharmaceuticals was founded in 2015. It employs 251 to 500 people.
Where is Felix Pharmaceuticals based?
Felix Pharmaceuticals is headquartered in Dublin, Ireland, in the Europe region.
How does Felix Pharmaceuticals make money?
Two revenue lines are on record. Product Sales are the primary driver. The others are licensing and Direct Sales.
Who are Felix Pharmaceuticals's main competitors?
Direct peers on record are Dechra Pharmaceuticals, Vetoquinol, Virbac, Norbrook Laboratories and Chanelle Pharma. Broad incumbents are Zoetis, Elanco Animal Health, Phibro Animal Health, Ceva Santé Animale and Boehringer Ingelheim Animal Health.
Does Felix Pharmaceuticals have an API?
No public API is recorded for Felix Pharmaceuticals.
What industry is Felix Pharmaceuticals in?
Felix Pharmaceuticals's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAM, Generic & Private-Label Veterinary Pharmaceuticals, with a secondary code of HLAMAEAA, Companion Animal Therapeutics (Rx). Its NAICS code is 325412 and its SIC code is 2834.